Stefano Barco1,2, Anke Adenaeuer1,3, Alice Trinchero4, Tanja Falter3, Karl J. Lackner1,3, Bernhard Lämmle1,5,6 and Heidi Rossmann1,3..
1
Center for Thrombosis and Hemostasis (CTH), University Medical Center
of the Johannes Gutenberg University Mainz, Mainz, Germany.
2 Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.
3
Institute of Clinical Chemistry and Laboratory Medicine, University
Medical Center of the Johannes Gutenberg University Mainz, Mainz,
Germany.
4 Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
5
Department of Hematology and Central Hematology Laboratory,
Inselspital, Bern University Hospital, University of Bern, Bern,
Switzerland.
6 Haemostasis Research Unit, University College London, London, UK.
Correspondence to: PD. Dr. Heidi Rossmann. Institute of Clinical
Chemistry and Laboratory Medicine, University Medical Center Mainz,
Langenbeckstrasse, 1, 55131 Mainz, Germany. E-mail:
heidi.rossmann@unimedizin-mainz.de
Published: March 1, 2021
Received: February 3, 2021
Accepted: February 14, 2021
Mediterr J Hematol Infect Dis 2021, 13(1): e2021027 DOI
10.4084/MJHID.2021.027
This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0),
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
|
To the editor.
We read the recently published letter to the editor by Dr. Girolami and Dr. Ferrari.[1]
While it does not add anything novel to our knowledge on severe
prekallikrein (PK) deficiency, it misleadingly reported on recent
works, which showed for the first time the much higher than the
anticipated prevalence of severe PK deficiency among subjects of
African origin.[2,3] Finally, Girolami and Ferrari
cited multiple reviews of the literature characterized by inadequate
methodology for systematic searches without, in contrast, citing the
sole comprehensive analysis of the clinical, laboratory, and genetic
characteristics of severe PK deficiency.[2] Furthermore, they discredited a follow-up paper as preliminary.[3]
In May 2020, we published a systematic study on severe PK deficiency,[2] the results of which had previously been presented at the American Society of Hematology Congress in December 2018.[4]
Among other findings, including the demonstration that some KLKB1
variants previously described in the literature as causal mutations for
PK deficiency represented, in fact, benign polymorphisms, we reported
two African patients from Ghana and Somalia, respectively, with the
same homozygous KLKB1 variant (c.451dupT, p.Ser151Phefs*34). This
variant has not been noticed in the international literature so far,
despite a minor allele frequency of 1.43% for African subjects,
according to the large Genome Aggregation Database (gnomAD). This datum
suggests that severe PK deficiency in Africans could be as common as
1/4725 general population just based on this unique mutation, which
appears predominant in this ethnic group,[2] but is
much less common in other groups. In a follow-up project intended to
substantiate the high prevalence of the KLKB1 c.451dupT mutation in
African origin subjects,[3] we investigated 300
healthy Nigerians and confirmed a high allele frequency (7/600 alleles
corresponding to 1.17%). In this manuscript, we provided a more
detailed analysis of the variant's frequency also by looking at other
genome databases, again confirming the high frequency in African
populations of different origin (native African, African-American, and
Afro-Caribbean).[3] In addition, in another severe PK deficient patient from Oman identified in,[2] we found out that he was also a homozygous carrier of c.451dupT,[3] and we identified another homozygous c.451dupT carrier from the literature,[5]
which turned out to be American of African origin after personal
communication with one of the authors (the ethnicity was not mentioned
in the manuscript).
Based on the aforementioned elements, we conclude that Girolami and Ferrari's letter to the editor is, at least, misleading.[1]
In particular, the sentence "defect present in 1.27% of 300 Nigerians"
is at the same time imprecise (it is unclear whether they refer to the
minor allele frequency or the prevalence of severe PK deficiency) and
incorrect (in our manuscript, a value of 1.17% was reported). Moreover,
and as detailed above, this published data is far more than
"preliminary", having been confirmed using data from different cohorts
and databases.[2,3] It comes indeed as a surprise that
this evidence has then been embraced by Drs. Girolami and Ferrari
without citing the original works correctly[2] or, as it is the case in a brief more recent communication from the same authors on the same topic, not citing them at all.[6]
Finally,
and beyond the discussion on the actual prevalence of severe PK
deficiency, we believe that our estimates of bleeding and
cardiovascular risks[2] represent the most reliable
figures available in the literature. Reasons for that are that (i)
these are provided both as age-stratified and depending on individual
follow-up time, (ii) prior analyses erroneously presented duplicated
data from different reports of the same case, (iii) the process of the
systematic review was conducted with adequate and transparent
methodology, also covering the grey literature and describing each step
of study selection in great detail.[2]
Multinational
cooperation involving global coagulation experts is being set up to
conduct the first international registry on severe PK deficiency and
answer open questions on this condition.
References
- Girolami A, Ferrari S. Worldwide Distribution of PK
Deficiency: the Defect Seems Mainly Concentrated in West African
Countries and the United States. Mediterr J Hematol Infect Dis. 2021;
13: e2021014. 10.4084/MJHID.2021.014. https://doi.org/10.4084/mjhid.2021.014 PMid:33489053 PMCid:PMC7813284
- Barco
S, Sollfrank S, Trinchero A, Adenaeuer A, Abolghasemi H, Conti L,
Hauser F, Kremer Hovinga JA, Lackner KJ, Loewecke F, Miloni E, Vazifeh
Shiran N, Tomao L, Wuillemin WA, Zieger B, Lammle B, Rossmann H. Severe
plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1
mutations, and estimated prevalence. J Thromb Haemost. 2020; 18:
1598-617. 10.1111/jth.14805. https://doi.org/10.1111/jth.14805 PMid:32202057
- Adenaeuer
A, Ezigbo ED, Fawzy Nazir H, Barco S, Trinchero A, Laubert-Reh D,
Strauch K, Wild PS, Lackner KJ, Lammle B, Rossmann H. c.451dupT in
KLKB1 is common in Nigerians, confirming a higher prevalence of severe
prekallikrein deficiency in Africans compared to Europeans. J Thromb
Haemost. 2020. 10.1111/jth.15137. https://doi.org/10.1111/jth.15137 PMid:33073460
- Barco
S, Sollfrank S, Trinchero A, Tomao L, Zieger B, Kremer-Hovinga JA,
Conti L, Adenäuer A, Miloni E, Lackner KJ, Rossmann H, Lammle B.
Detection and Differential Diagnosis of Prekallikrein Deficiency:
Genetic Study of New Families and Systematic Review of the Literature.
Blood. 2018; 132 (Supplement 1): 2496. https://doi.org/10.1182/blood-2018-99-116030
- Dasgupta
SK, Rivera S, Thiagarajan P. Lisinopril-Induced Angioedema in a Patient
with Plasma Prekallikrein Deficiency. TH Open. 2020; 4: e33-e5.
10.1055/s-0040-1701238. https://doi.org/10.1055/s-0040-1701238 PMid:31984307 PMCid:PMC6978173
- Girolami
A, Ferrari S, Girolami B. Prevalence of Cardiovascular Disorders in
African-Americans With Congenital Prekallikrein Deficiency Versus
Caucasians-Americans With the Same Defect. Clin Appl Thromb Hemost.
2020; 26: 1076029620972481. 10.1177/1076029620972481. https://doi.org/10.1177/1076029620972481 PMid:33176434 PMCid:PMC7672757
[TOP]